EX1
Director Trades
| Date | Director | Value |
|---|
Company News
Exopharm developing novel Plexaris product to deliver anti-cancer drug into target cells
Clinical stage regenerative medicine company Exopharm (ASX: EX1) has published test results that suggest its Plexaris product, made up of engineered exosomes through “LEAP technology”, can effectively deliver therapeutic drugs into target cells. Plexaris is already being tested in humans as part of the PLEXOVAL phase 1 trial for wound healing although its multifaceted applications are […]
Exopharm publishes ‘positive and unique’ results for its exosome platform
Regenerative medicine company Exopharm (ASX: EX1) has received amiable results from a BioMAP testing program operated by Eurofins with respect to its exosome products. Results showed that Exopharm’s exosome platform is safe in its mechanism of action and that has “different and distinct activities” compared to 4,500 other drugs. Strong lab results raise the chances […]
